Last reviewed · How we verify
Mycophenolic Acid 0.3%
At a glance
| Generic name | Mycophenolic Acid 0.3% |
|---|---|
| Sponsor | Surface Ophthalmics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma (PHASE2)
- A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease (PHASE2)
- Study of Salvage Therapy to Treat Patients with Granulomatosis with Polyangiitis (PHASE3)
- Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation (PHASE4)
- Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome (PHASE2)
- Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols (PHASE4)
- Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders (PHASE1, PHASE2)
- A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mycophenolic Acid 0.3% CI brief — competitive landscape report
- Mycophenolic Acid 0.3% updates RSS · CI watch RSS
- Surface Ophthalmics, Inc. portfolio CI